Biotech Values

[DewDiligence]

…but likely PFE will terminate some promising partnerships, and if the stocks react badly there might be a buying opportunity.

Perhaps; however, I was thinking PFE is more likely to try to sublicense out the stuff it no longer wants the way NVS did with Iloperidone.